OSCR

IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

A correction to this paper has been published: the notice, 42547583, from Europe PMC.

Overview

Authors: Lukas Bunse1,2,3,4,5,6, Katharina Lindner1,3,6,7, Antje Wick8, Angelika Freitag9, Lisa-Marie Lanz9, Dominic Edelmann9, Abigail Suwala10, Michael O. Breckwoldt11, Inga Harting11, Felix Sahm10,12, Richard F. Schlenk3,9,13, Anita Schmitt14, Oliver Schnell15, Jörg Hense16, Martin Misch17, Dietmar Krex18, Monika Denk19,20,21, Juliane Walz19,20,21, Joachim P. Steinbach22, Andreas von Deimling10,12
and 7 other authorsMichael Schmitt14, Theresa Bunse1,2,3, Ghazaleh Tabatabai19,21,23,24, Martin Bendszus11, Isabel Poschke1,3,7, Wolfgang Wick3,4,8,25, Michael Platten1,2,3,4,5,6,7,26
26 affiliations
  1. DKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ),Heidelberg, Germany
  2. Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg,Mannheim, Germany
  3. German Cancer Consortium (DKTK), DKFZ, Core Center,Heidelberg, Germany
  4. Hertie Network of Excellence in Clinical Neuroscience, Tübingen, Germany
  5. DKFZ-Hector Cancer Institute at University Medical Center Mannheim,Mannheim, Germany
  6. Cluster of Excellence SynthImmune (EXC 3018/1) “Engineering Immune function with Synthetic Biology”, University of Heidelberg,Mannheim, Germany
  7. Immune Monitoring Unit, National Center for Tumor Diseases (NCT),Heidelberg, Germany
  8. Neurology Clinic and European Center for Neurooncology (EZN), Heidelberg University Hospital, University of Heidelberg,Heidelberg, Germany
  9. NCT Trial Management and Services, NCT, and German Cancer Research Center (DKFZ),Heidelberg, Germany
  10. Department of Neuropathology, Heidelberg University Hospital, University of Heidelberg,Heidelberg, Germany
  11. Department of Neuroradiology, Heidelberg University Hospital, University of Heidelberg,Heidelberg, Germany
  12. DKTK CCU Neuropathology, DKFZ,Heidelberg, Germany
  13. Department of Medical Oncology, Heidelberg University Hospital, University of Heidelberg,Heidelberg, Germany
  14. Department of Internal Medicine V, Heidelberg University Hospital, University of Heidelberg,Heidelberg, Germany
  15. Neurosurgery Clinic, University Hospital Erlangen,Erlangen, Germany
  16. Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen,Essen, Germany
  17. Department of Neurosurgery, Charité Medical Center, University of Berlin,Berlin, Germany
  18. Technische Universität Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, Department of Neurosurgery,Dresden, Germany
  19. Cluster of Excellence iFIT (EXC2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, University of Tübingen,Tübingen, Germany
  20. Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen,Tübingen, Germany
  21. German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), partner site Tübingen,Tübingen, Germany
  22. Dr. Senckenberg Institute of Neurooncology,Frankfurt, Germany
  23. Department of Neurology and Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen,Tübingen, Germany
  24. Center for Neuro-Oncology, CCC Tübingen-Stuttgart in CCC-SW, Tübingen, Germany
  25. DKTK CCU Neurooncology, DKFZ,Heidelberg, Germany
  26. Helmholtz Institute for Translational Oncology (HI-TRON) Mainz, German Cancer Research Center,Mainz, Germany
Journal: Nature cancer, volume 7, issue 8, pages 1300-1311
Dates: received 30 October 2025; accepted 8 June 2026; published online 1 July 2026; in print 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.1038/s43018-026-01199-y · PMID 42387024 · PMCID PMC13498463 · OpenAlex W7166862076
Open access: hybrid, a free copy (OpenAlex)
Categories: human (organism), other condition (population), cellular / molecular (subfield)
Methods: Statistics
Keywords: CNS cancer, Tumour immunology, Peptide vaccines, Cancer
MeSH: Astrocytoma*, Brain Neoplasms*, Cancer Vaccines*, Isocitrate Dehydrogenase*, Mutation*, Adult, Aged, Female, Humans, Male, Middle Aged, Protein Subunit Vaccines, Vaccines, Subunit (* major topic)
Topic: Glioma Diagnosis and Treatment (Oncology, Medicine), according to OpenAlex
Citations: cited by 2 papers (Europe PMC); 39 references in the paper
Research resources: we used SAMtools mpileup RRID:SCR_002105, RRID:SCR_012891
Notices: A correction to this paper has been published (42547583, from Europe PMC)

Abstract

The clonal glioma driver mutation IDH1R132H gives rise to a major histocompatibility class II-restricted neoepitope. A multicenter, first-in-human phase 1 trial met its prespecified primary endpoints by demonstrating safety and immunogenicity of an IDH1-R132H peptide vaccine (IDH1-vac) integrated into standard of care in 33 participants with newly diagnosed grade III and IV (World Health Organization classification 2007) IDH1-R132H+ astrocytomas (NOA16). Here we report on the clinical and immunological long-term follow-up of this trial as secondary and translational endpoints. The 8-year progression-free and overall survival (OS) rates were 0.42 (confidence interval (CI): 0.24–0.59) and 0.66 (CI: 0.46–0.79), respectively. For participants with grade IV astrocytoma, median OS was 106.1 months (CI: 39.6–not estimable (NE)), comparing favorably to the published median OS in this population ranging from 31.6–56.4 months. Within the responder group, sustained antibody responses to IDH1-R132H were associated with a favorable long-term clinical course. IDH1-vac-induced T cell responses were detected in the inflamed brain lesion of an IDH1-vac-associated pseudoprogression, whereas no IDH1-vac-induced T cells were found in participants with early progressive disease. The favorable long-term outcome of the NOA16 cohort supports investigating IDH1-vac in persons with newly diagnosed grade 3 and 4 (World Health Organization classification 2021) IDH-mutant astrocytomas in a randomized phase 2 trial (ClinicalTrials.gov identifier: NCT02454634).

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Code availability

No code was developed for this study.

Reproduced under the paper's license (CC BY), from the paper cited above.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Data availability

Single-cell RNA-seq data that are associated with Fig. 3 were deposited to the National Center for Biotechnology Information Sequence Read Archive under accession codes SRR12880623 (https://www.ncbi.nlm.nih.gov/sra/?term=SRR12880623) and SRR12880624 (https://www.ncbi.nlm.nih.gov/sra/?term=SRR12880624) and are publicly accessible. Paired αβ TCR sequence information has not been deposited for patent considerations of mutant IDH-reactive TCR motifs. TCRB sequencing data associated with Fig. 3 are available online (https://clients.adaptivebiotech.com/immuneaccess). Data that support the study findings are available to researchers upon reasonable request to the corresponding authors, if in alignment with study consent and in nonidentifiable format to protect participant privacy. Source data are provided with this paper.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 2, 28 September 2026

  • Publisher: n/a → Nature Portfolio

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 27 authors, 4 keywords, 13 MeSH terms, 1 funder, 39 references, 2 RRIDs, 1 integrity notice.

Cite

This paper

Bunse, L., Lindner, K., Wick, A., Freitag, A., Lanz, L.-M., Edelmann, D., Suwala, A., Breckwoldt, M. O., Harting, I., Sahm, F., Schlenk, R. F., Schmitt, A., Schnell, O., Hense, J., Misch, M., Krex, D., Denk, M., Walz, J., Steinbach, J. P., . . . Platten, M. (2026). IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial. Nature cancer, 7(8), 1300-1311. https://doi.org/10.1038/s43018-026-01199-y

BibTeX

@article{bunse2026idh1,
author = {Bunse, Lukas and Lindner, Katharina and Wick, Antje and Freitag, Angelika and Lanz, Lisa-Marie and Edelmann, Dominic and Suwala, Abigail and Breckwoldt, Michael O. and Harting, Inga and Sahm, Felix and Schlenk, Richard F. and Schmitt, Anita and Schnell, Oliver and Hense, Jörg and Misch, Martin and Krex, Dietmar and Denk, Monika and Walz, Juliane and Steinbach, Joachim P. and von Deimling, Andreas and Schmitt, Michael and Bunse, Theresa and Tabatabai, Ghazaleh and Bendszus, Martin and Poschke, Isabel and Wick, Wolfgang and Platten, Michael},
title = {{IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial}},
journal = {Nature cancer},
year = {2026},
month = jul,
volume = {7},
number = {8},
pages = {1300--1311},
publisher = {Nature Portfolio},
issn = {2662-1347},
doi = {10.1038/s43018-026-01199-y},
url = {https://doi.org/10.1038/s43018-026-01199-y},
pmid = {42387024},
pmcid = {PMC13498463}
}

RIS

TY - JOUR
AU - Bunse, Lukas
AU - Lindner, Katharina
AU - Wick, Antje
AU - Freitag, Angelika
AU - Lanz, Lisa-Marie
AU - Edelmann, Dominic
AU - Suwala, Abigail
AU - Breckwoldt, Michael O.
AU - Harting, Inga
AU - Sahm, Felix
AU - Schlenk, Richard F.
AU - Schmitt, Anita
AU - Schnell, Oliver
AU - Hense, Jörg
AU - Misch, Martin
AU - Krex, Dietmar
AU - Denk, Monika
AU - Walz, Juliane
AU - Steinbach, Joachim P.
AU - von Deimling, Andreas
AU - Schmitt, Michael
AU - Bunse, Theresa
AU - Tabatabai, Ghazaleh
AU - Bendszus, Martin
AU - Poschke, Isabel
AU - Wick, Wolfgang
AU - Platten, Michael
TI - IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial
T2 - Nature cancer
J2 - Nat Cancer
PY - 2026
DA - 2026/07/01
VL - 7
IS - 8
SP - 1300
EP - 1311
SN - 2662-1347
PB - Nature Portfolio
DO - 10.1038/s43018-026-01199-y
UR - https://doi.org/10.1038/s43018-026-01199-y
LA - en
ER -

CSL-JSON

{
"id": "10.1038/s43018-026-01199-y",
"type": "article-journal",
"title": "IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial",
"container-title": "Nature cancer",
"author": [
{
"family": "Bunse",
"given": "Lukas"
},
{
"family": "Lindner",
"given": "Katharina"
},
{
"family": "Wick",
"given": "Antje"
},
{
"family": "Freitag",
"given": "Angelika"
},
{
"family": "Lanz",
"given": "Lisa-Marie"
},
{
"family": "Edelmann",
"given": "Dominic"
},
{
"family": "Suwala",
"given": "Abigail"
},
{
"family": "Breckwoldt",
"given": "Michael O."
},
{
"family": "Harting",
"given": "Inga"
},
{
"family": "Sahm",
"given": "Felix"
},
{
"family": "Schlenk",
"given": "Richard F."
},
{
"family": "Schmitt",
"given": "Anita"
},
{
"family": "Schnell",
"given": "Oliver"
},
{
"family": "Hense",
"given": "Jörg"
},
{
"family": "Misch",
"given": "Martin"
},
{
"family": "Krex",
"given": "Dietmar"
},
{
"family": "Denk",
"given": "Monika"
},
{
"family": "Walz",
"given": "Juliane"
},
{
"family": "Steinbach",
"given": "Joachim P."
},
{
"family": "von Deimling",
"given": "Andreas"
},
{
"family": "Schmitt",
"given": "Michael"
},
{
"family": "Bunse",
"given": "Theresa"
},
{
"family": "Tabatabai",
"given": "Ghazaleh"
},
{
"family": "Bendszus",
"given": "Martin"
},
{
"family": "Poschke",
"given": "Isabel"
},
{
"family": "Wick",
"given": "Wolfgang"
},
{
"family": "Platten",
"given": "Michael"
}
],
"container-title-short": "Nat Cancer",
"volume": "7",
"issue": "8",
"page": "1300-1311",
"DOI": "10.1038/s43018-026-01199-y",
"PMID": "42387024",
"PMCID": "PMC13498463",
"ISSN": "2662-1347",
"publisher": "Nature Portfolio",
"URL": "https://doi.org/10.1038/s43018-026-01199-y",
"language": "en",
"issued": {
"date-parts": [
[
2026,
7,
1
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1158/1078-0432.ccr-21-1881
T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
In common: other condition, 4 references, 5 authors
[2] doi:10.1158/1078-0432.ccr-23-0926
Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
In common: other condition, 3 references, 4 authors
[3] doi:10.1038/s43856-023-00381-y
Concurrent gliomas in patients with multiple sclerosis.
Journal: Communications medicine
In common: other condition, 2 references, 4 authors
[4] doi:10.1093/neuonc/noac138 [code]
Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
Journal: Neuro-oncology
In common: other condition, cellular / molecular, 3 references, 3 authors
[5] doi:10.1038/s43018-024-00904-z [code]
Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics.
Journal: Nature cancer
In common: other condition, 3 references, 3 authors
[6] doi:10.1093/neuonc/noaf015 [code]
The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant.
Journal: Neuro-oncology
In common: other condition, 3 references, 3 authors
[7] doi:10.1038/s41467-025-56268-0
Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics.
Journal: Nature communications
In common: other condition, cellular / molecular, 4 references, 2 authors
[8] doi:10.1038/s41467-023-36321-6 [code]
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles.
Journal: Nature communications
In common: other condition, cellular / molecular, 2 references, 2 authors
[9] doi:10.1038/s41467-025-57078-0 [code]
Explainable artificial intelligence of DNA methylation-based brain tumor diagnostics.
Journal: Nature communications
In common: other condition, 2 references, 2 authors
[10] doi:10.1038/s41467-024-45067-8 [code]
A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1.
Journal: Nature communications
In common: other condition, 1 reference, 2 authors

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.